The efficacy and safety of cannabinoids for the treatment of mental disorders and substance use disorders: a systematic review and meta-analysis - PubMed

3 hours ago

Cannabinoids were studied for treating mental disorders and substance use disorders (SUDs) via a systematic review and meta-analysis of 54 randomized controlled trials (RCTs).
Key findings include a reduction in cannabis withdrawal symptoms and use in cannabis use disorder, and reduced tic severity in Tourette's Syndrome.
Cannabinoids improved sleep time in insomnia and reduced autistic traits in autism spectrum disorder but increased cocaine craving in cocaine use disorder.
No significant effects were found for anxiety, anorexia nervosa, psychotic disorders, PTSD, or opioid use disorder.
Cannabinoids were associated with higher odds of all-cause adverse events (OR 1.75) but not serious adverse events.
The quality of evidence was generally low, with 44% of trials having a high risk of bias.
Routine use of cannabinoids for mental disorders and SUDs is rarely justified due to limited high-quality evidence.

Hasty Briefsbeta